Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
As a physician, discussing the use of peptides like BPC with patients can be challenging, as recommending them in a hospital setting could result in license revocation, but having an open discussion in a clinic setting could be a more suitable approach 2m6s
It is not the solution on its own
Kentuckians may recognize the following brand names of GLP-1 weight loss drugs: Ozempic (semaglutide from Novo Nordisk) Rybelsus (semaglutide from Novo Nordisk) Wegovy (semaglutide from Novo Nordisk) Mounjaro (tirzepatide from Eli Lilly and Company) Zepbound (tirzepatide from Eli Lilly and Company) Saxenda (liraglutide from Novo Nordisk) Victoza (liraglutide from Novo Nordisk) Trulicity (dulaglutide from Eli Lilly and Company) Bursor & Fisher, P.A
In 2023, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed reports of thyroid cancer and pancreatitis associated with GLP-1 receptor agonists but concluded there was no causal link for thyroid cancer and did not recommend changes to prescribing guidance based on pancreatic cancer concerns
The complementary nature of these peptides extends across multiple levels
These are not bureaucratic hurdles
